A study of Smad4, Smad6 and Smad7 in surgically resected samples of pancreatic ductal adenocarcinoma and their correlation with clinicopathological parameters and patient survival

被引：10

作者：

Singh P. ^{[1
]}

Srinivasan R. ^{[2
]}

Wig J. ^{[1
]}

Radotra B. ^{[3
]}

机构：

[1] Department of General Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh

[2] Department of Cytology and Gynaecological Pathology, Postgraduate Institute of Medical Education and Research, Chandigarh

[3] Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh

来源：

BMC Research Notes | / 4卷 / 1期

关键词：

clinicopathological parameters; Pancreas; pancreatic adenocarcinoma; prognosis; Smad4; Smad6; Smad7;

D O I：

10.1186/1756-0500-4-560

中图分类号：

学科分类号：

摘要：

Background: Smad4 is the common mediator of the tumor suppressive functions of TGF-beta. Smad6 and Smad7 are the antagonists of the TGF-beta pathway. This study investigates the differential protein expressions of Smad4, Smad6 and Smad7 in tumor as compared to normal tissue of pancreatic ductal adenocarcinoma (PDAC) and compares them with clinicopathological parameters and patient survival. Results: There was a significant difference in protein expressions of Smad4 (p = 0.0001), Smad6 (p = 0.0015) and Smad7 (p = 0.0005) protein in tumor as compared to paired normal samples. Loss of Smad7 expression correlated significantly with tumor size (r = 0.421, p < 0.036) and margin status (r = 0.431; p <.032). Patients with moderate to high Smad4 protein expression had a better survival (median survival = 14.600 2.112 months) than patients with absent or weak Smad4 protein expression (median survival = 7.150 0.662). In addition, advanced disease stage correlated significantly with poor prognosis. Conclusion: Loss of Smad4 significantly correlated with poor survival of PDAC patients. In the cases where Smad4 is expressed, Smad6 inhibition is possibly a novel mechanism for Smad4 inactivation. Smad7 has a role in pathobiology of PDAC. Further investigation in the roles of Smad6 and Smad7 would help in the identification of novel therapeutic targets for PDAC. © 2011 Singh et al; licensee BioMed Central Ltd.

引用

共 29 条

[1]

Wrana J.L., Attisano L., Wieser R., Ventura F., Massague J., Mechanism of activation of the TGF-beta receptor, Nature, 370, pp. 341-347, (1994)

[2]

Massague J., TGF- signal transduction, Annual Review of Biochemistry, 67, pp. 753-791, (1998)

[3]

Souchelnytskyi S., Tamaki K., Engstrom U., Wernstedt C., Ten Dijke P., Heldin C.-H., Phosphorylation of Ser <sup>465</sup> and Ser <sup>467</sup> in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor- signaling, Journal of Biological Chemistry, 272, 44, pp. 28107-28115, (1997)

[4]

De Caestecker M.P., Yahata T., Wang D., Parks W.T., Huang S., Hill C.S., Shioda T., Roberts A.B., Lechleider R.J., The Smad4 activation domain (SAD) is a proline-rich, p300-dependent transcriptional activation domain, Journal of Biological Chemistry, 275, 3, pp. 2115-2122, (2000)

[5]

De Winter J.P., Roelen B.A.J., Ten Dijke P., Van Der Burg B., Van Den Eijnden-Van Raaij A.J.M., DPC4 (SMAD4) mediates transforming growth factar-1 (TGF-1) induced growth inhibition and transcriptional response in breast tumour cells, Oncogene, 14, 16, pp. 1891-1899, (1997)

[6]

Hayashi H., Abdollah S., Qiu Y., Cai J., Xu Y.-Y., Grinnell B.W., Richardson M.A., Topper J.N., Gimbrone Jr. M.A., Wrana J.L., Falb D., The MAD-related protein Smad7 associates with the TGF receptor and functions as an antagonist of TGF signaling, Cell, 89, 7, pp. 1165-1173, (1997)

[7]

Imamura T., Takase M., Nishihara A., Oeda E., Hanai J.-I., Kawabata M., Miyazono K., Smad6 inhibits signalling by the TGF- superfamily, Nature, 389, 6651, pp. 622-626, (1997)

[8]

Singh P., Srinivasan R., Wig J.D., Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment, Pancreas, 40, pp. 644-652, (2011)

[9]

Van Heek T., Rader A.E., Offerhaus G.J.A., McCarthy D.M., Goggins M., Hruban R.H., Wilentz R.E., K-ras, p53, and DPC4 (MAD4) alterations in fine-needle aspirates of the pancreas: A molecular panel correlates with and supplements cytologic diagnosis, American Journal of Clinical Pathology, 117, 5, pp. 755-765, (2002)

[10]

Hahn S.A., Schutte M., Hoque A.T., Moskaluk C.A., Da Costa L.T., Rozenblum E., Weinstein C.L., Fischer A., Yeo C.J., Hruban R.H., Kern S.E., DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1, Science, 271, pp. 350-353, (1996)

← 1 2 3 →